Cladribine is a medicine used to treat certain types of blood cancer, like hairy-cell leukemia. It works by stopping the growth of cancer cells. It's given as an injection.
Every report comes from a Lived member, sent anonymously.
Have you tried Cladribine for Hairy Cell Leukemia?
Cladribine is a prescription medicine that lowers the number of lymphocytes, a type of white blood cell. It is used in two very different ways, and the two forms should not be confused. Cladribine tablets, sold as Mavenclad and also available as a generic, treat relapsing forms of multiple sclerosis (MS) in adults. This includes relapsing-remitting MS and active secondary progressive MS, the stage where disability builds gradually but relapses or new MRI activity still occur. Because of its risks, including cancer and serious infections, it is generally used after another MS medicine has not worked well enough or could not be tolerated. It is not recommended for a first isolated MS-like episode (clinically isolated syndrome). Cladribine injection is a chemotherapy medicine for hairy cell leukemia, a rare, slow-growing blood cancer. It is used when the leukemia causes low blood counts or symptoms; people without these problems are often watched rather than treated. The original injectable brand, Leustatin, has been discontinued in the US, and generic versions are used instead. Specialists often combine it with rituximab, an antibody medicine that targets the same leukemia cells.
Cladribine is built to resemble one of the building blocks of DNA. Lymphocytes contain high levels of an enzyme that converts cladribine into its active form and relatively little of the machinery that breaks it down, so the drug builds up inside these cells. There it disrupts the making and repair of DNA, and the cells die. Unlike many chemotherapy drugs, it can kill lymphocytes that are resting as well as those that are dividing. In hairy cell leukemia, the cancerous cells are a kind of lymphocyte, so they are especially vulnerable. In MS, the immune system attacks the protective coating around nerves in the brain and spinal cord, and B and T lymphocytes drive that attack. Short courses of cladribine tablets reduce these cells for months. As the immune system gradually rebuilds, the attacks appear to stay quieter, which is why two brief yearly courses can have an effect lasting years. Researchers do not fully understand why the benefit outlasts the drop in lymphocytes.
For MS, the total dose is based on body weight and spread over two yearly treatment courses. Each course has two short cycles about a month apart. In each cycle, a person takes 1 or 2 tablets once a day for 4 or 5 days in a row, so there are about 8 to 10 tablet days per year. After the two courses, no more cladribine is given for at least the next 2 years, because treating again sooner was linked to more cancers in studies. Whether restarting after that is safe and helpful has not been studied. The tablets are a cytotoxic drug, meaning they can harm healthy cells, so handling matters. Swallow each tablet whole with water as soon as it comes out of the blister, without chewing. Handle tablets with dry hands and wash your hands afterward. On tablet days, take any other medicine by mouth at least 3 hours apart from cladribine. If a dose is missed, take it later the same day if you remember; otherwise take it the next day and add a day to that cycle. Never double up. For hairy cell leukemia, the US label gives one course as a continuous infusion into a vein over 7 days. Many specialists now give it instead as a shot under the skin once a day for 5 days. If the leukemia does not respond to a first course, another course of cladribine alone is unlikely to help.
With the MS tablets, the most common side effects in studies were colds and other upper respiratory infections, headache and low lymphocyte counts. Nausea, back or joint pain, trouble sleeping and mild hair thinning were less common. Lymphocyte counts fall in most people, reaching their lowest point about 2 to 3 months after the start of each course and then slowly recovering. Shingles and cold sores were more frequent than with placebo, especially when counts were very low. A few problems need a prompt call to the prescriber. Liver injury is uncommon but can be serious and most often appears about a month after starting; yellowing of the skin or eyes, dark urine, or unexplained nausea, vomiting, belly pain or tiredness should be reported right away. A painful blistering rash can be shingles, and an infection that is not clearing may mean the immune system needs help; both should be reported promptly so treatment can start. Shortness of breath, a racing or irregular heartbeat or unusual swelling can be signs of heart failure and also need a prompt call. A new rash, especially with mouth sores, can be an allergic reaction; stop the tablets and contact the prescriber. Weakness on one side of the body, clumsiness, vision changes or confusion that build over days can rarely signal a serious brain infection and also need prompt attention. Swelling of the face, lips, tongue or throat, or trouble breathing, can mean a serious allergic reaction: stop the tablets and get emergency care right away. With the leukemia injection, blood counts usually drop further during the first weeks before they recover, raising the risk of infection and bleeding. Fever is very common in the first month, and fatigue, nausea, rash and headache also occur. Because infection can become serious quickly when white cell counts are low, a fever in the first weeks after treatment should be reported to the treatment team right away, day or night, following the plan they provide.
The MS tablets carry an FDA boxed warning for two risks. First, they may increase the risk of cancer. They are not used in someone who currently has cancer, people with a past cancer or higher risk need an individual decision, and routine cancer screening should continue. Second, cladribine can cause serious birth defects. Pregnancy must be ruled out before each course. Women who could become pregnant need effective birth control during treatment and for 6 months after the last dose of each course, and men need it for 14 weeks after. Anyone who becomes pregnant should stop and contact the prescriber. Breastfeeding should be avoided on tablet days and for 10 days after the last dose. The leukemia injection also carries a risk of fetal harm and calls for highly effective birth control during treatment. Because cladribine weakens immune defenses, the tablets are not used in people with HIV or active chronic infections such as tuberculosis or hepatitis. Screening for these comes first, since hidden tuberculosis or hepatitis B can flare. People without immunity to chickenpox (checked with a blood test) are vaccinated before starting, and the non-live (recombinant) shingles vaccine is recommended for those who have. Live vaccines must be given at least 4 to 6 weeks before treatment and avoided while blood counts are low. Cladribine is generally not combined with other medicines that suppress the immune system or bone marrow, though a short course of steroids for an MS relapse is acceptable. Certain antiviral medicines, including some used for HIV or hepatitis C, can interfere with how cladribine works, and some heart, blood and anti-inflammatory medicines can change how much reaches the body during the tablet days, so a pharmacist should review every medicine and supplement. If a blood transfusion is ever needed, the blood should be irradiated to prevent a rare reaction in which donor white cells attack the body while immunity is weakened, so tell the care team you have had cladribine. People with moderate to severe liver disease or significant kidney disease may not be suitable candidates.
Before starting the MS tablets, expect blood tests, infection screening, a recent MRI scan and a check of vaccinations and pregnancy status. Blood counts are repeated 2 and 6 months after the start of each course, and liver tests before each cycle. The second year's course is delayed if lymphocytes have not recovered enough, and if recovery takes more than 6 months, no further treatment is given. In the main two-year study, cladribine tablets cut the yearly relapse rate by 58% compared with placebo: about 81% of people had no relapse, versus 63% on placebo. Fewer people had disability that worsened and stayed worse (13% versus 19%). A practical appeal is that most of the year involves no medicine at all. The trade-off is that the effect cannot be switched off quickly, the cancer and infection questions extend beyond the dosing days, and response varies from person to person. Ongoing MRI and neurology follow-up show whether the disease stays quiet. For hairy cell leukemia, blood counts typically return to normal over about 2 months, and a complete response, with no leukemia cells found in the blood or bone marrow, usually takes several months to confirm. Many people stay in remission for years after one course, though relapse can happen and can often be treated again. Immune recovery is slow, so specialists commonly prescribe preventive antibiotics and antivirals for at least 6 months, along with regular skin checks.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Cladribine, what you've noticed, or ask the community a question.